Last reviewed · How we verify
NCT07080359
Isavuconazole in Critically Ill Patients: Efficacy and Safety
trial testing Isavuconazole treatment in Fungal Infection in 75 participants. Not yet recruiting.
31 December 2029
Quick facts
| Lead sponsor | Shanghai 10th People's Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 1 August 2025 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2030 |
Drugs / interventions tested
- Isavuconazole treatment — full drug profile →
Conditions studied
- Fungal Infection — all drugs for Fungal Infection →
- Aspergillosis — all drugs for Aspergillosis →
- Mucormycosis — all drugs for Mucormycosis →
Sponsor
Shanghai 10th People's Hospital
Who can join
18 and older, any sex, with Fungal Infection or Aspergillosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability. This study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes: 1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients; 2. Clinical outcomes; 3. Adverse effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07080359
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fungal Infection
Currently open trials in the same condition.
- NCT07238114 — Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors · active not recruiting
- NCT06510699 — Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial · Phase 2 · recruiting
- NCT05814432 — Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS · Phase 3 · recruiting
- NCT03717623 — Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants · Phase 4 · recruiting
- NCT03828773 — PTX3-targeted Antifungal Prophylaxis · NA · recruiting
Other Shanghai 10th People's Hospital trials
Trials by the same sponsor.
- NCT07528040 — An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With C · not yet recruiting
- NCT07370441 — Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients · Phase 4 · not yet recruiting
- NCT07328100 — Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. · NA · not yet recruiting
- NCT06783296 — Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension · NA · not yet recruiting
- NCT07204496 — A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07080359 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai 10th People's Hospital
- Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07080359.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing